MediciNova's MN-166 (Ibudilast) Advances Toward Pivotal ALS Data as Phase 2b/3 COMBAT-ALS Trial Completes Enrollment
核心洞察
MediciNova has completed enrollment in the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (搜索), with 234 participants across the US and Canada and topline data expected by end of 2026.
MN-166 is a CNS-penetrant small molecule with a multi-target mechanism including MIF (搜索), PDE (搜索), and TLR4 (搜索) inhibition, holding both Orphan Drug Designation and Fast Track status from the US FDA.
The NIH-funded SEA-NOBI-ALS study targeting late-stage ALS patients has activated 12 US sites and enrolled 100 of 200 planned participants as of January 2026, supported by $22 million in funding.
MediciNova has reached a critical milestone in its late-stage amyotrophic lateral sclerosis (搜索) (ALS) program, completing enrollment in the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast). The randomized, controlled study involves 234 participants across the United States and Canada, with topline data expected by the end of 2026. The trial targets a global ALS market valued at over $3 billion, where treatment options remain severely limited.
The COMBAT-ALS trial evaluates the efficacy, safety, and functionality of MN-166 over a 12-month treatment period, using a combined function and survival primary endpoint. The study builds on earlier Phase 2a results in which the MN-166 group demonstrated a higher proportion of responders across functional and quality-of-life measures.
Mechanism of Action and Differentiation
MN-166 (ibudilast) is a CNS-penetrant small molecule that operates through multiple mechanisms, including macrophage migration inhibitory factor (MIF (搜索)) inhibition, phosphodiesterase (PDE (搜索)) inhibition, and toll-like receptor 4 (TLR4 (搜索)) inhibition. This multi-target approach is designed to reduce neuroinflammation and promote neuroprotection, distinguishing it from other investigational ALS therapies. The drug is administered orally, offering a practical advantage over parenteral alternatives, and targets a broad ALS patient population.
Regulatory Designations and Market Positioning
MN-166 holds Orphan Drug Designation from both the US FDA and the European Medicines Agency for ALS and other potential indications. It has also secured Fast Track designation from the FDA, which could accelerate regulatory interactions and review timelines while providing incentives such as extended market exclusivity upon approval. MediciNova has further strengthened its intellectual property position with US patents covering extended-release formulations of MN-166, ensuring market exclusivity until at least 2040. The company is also exploring future formulations, including parenteral options, to broaden clinical applicability.
NIH-Funded SEA-NOBI-ALS Study
In parallel with COMBAT-ALS, the NIH-funded SEA-NOBI-ALS study is targeting late-stage ALS patients. As of January 2026, 12 US sites had been activated and 100 of the planned 200 participants had been enrolled. The study is supported by $22 million in NIH funding, reflecting significant government investment in MN-166's potential. MediciNova reported that enrollment had reached 50% at that time.
Multi-Indication Development Strategy
Beyond ALS, MediciNova is pursuing a broad development strategy for MN-166 across multiple indications with substantial unmet medical need. In degenerative cervical myelopathy (搜索) (DCM), the program is progressing toward Phase III development. Phase II research is underway in long COVID and substance use disorders. The Phase II OXTOX trial in chemotherapy-induced peripheral neuropathy (搜索) (CIPN) is nearing completion, with results anticipated in 2026.
Prior clinical evidence in progressive multiple sclerosis (搜索) has also been encouraging. The Phase IIb SPRINT-MS study linked MN-166 to a 26% reduction in disability progression and slower brain atrophy in progressive MS. Ibudilast's mechanism of inhibiting pro-inflammatory cytokines and promoting neurotrophic factors supports its potential role across chronic neurological disorders.
Financial Position and Partnership Model
MediciNova operates a capital-efficient model, reporting $27.3 million in cash with no debt and an annual burn rate of $12–13 million, providing runway through key upcoming milestones. The company's academic and government partnerships fully fund non-core programs, offering non-dilutive revenue opportunities. Multiple late-stage assets are positioned for commercial partnerships, with additional pipeline indications spanning neurological, fibrotic, and metabolic diseases.
MN-166 and the company's other late-stage asset, MN-001, both have well-established safety profiles, Orphan Drug Designation, and Fast Track status. The upcoming COMBAT-ALS topline readout at the end of 2026 represents a potentially transformative event for the ALS treatment landscape, where high unmet need persists despite ongoing therapeutic advances.